Aisling Capital Management LP
CIK 1766721
13F filing for Q2 2026・No. 4,040
- Holdings
- US$471.62M
- Quarter change
- −US$4.67M
- Entries
- 14
- Net bought (estimate)
- −US$35.36M
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 1
- Sold out 0
- Cut 1
- Added 0
- Corporate actions 0
- Unchanged 12
Largest holdings
14 stocks worth US$471.62M, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| BBIOBRIDGEBIO PHARMA INCCOM | Cut | 4,589,611 | US$341.83M | 72.48% |
| GLUEMONTE ROSA THERAPEUTICS INCCOM | Unchanged | 1,555,664 | US$37.65M | 7.98% |
| SYNDAX PHARMACEUTICALS INCCOM | Unchanged | 1,316,806 | US$28.79M | 6.10% |
| CMPSCOMPASS PATHWAYS PLCSPONSORED ADS | Unchanged | 1,432,336 | US$20.27M | 4.30% |
| BICARA THERAPEUTICS INCCOM | Unchanged | 568,919 | US$16.89M | 3.58% |
| BRIDGEBIO ONCOLOGY THERAPEUTCOM NEW | Unchanged | 1,018,018 | US$7.76M | 1.64% |
| SCHOLAR ROCK HLDG CORPCOM | Unchanged | 77,031 | US$4.24M | 0.90% |
| URGNUROGEN PHARMA LTDCOM | Unchanged | 108,000 | US$3.97M | 0.84% |
| BIOMEA FUSION INCCOM | Unchanged | 2,048,757 | US$3.01M | 0.64% |
| ACLARIS THERAPEUTICS INCCOM | Unchanged | 434,455 | US$2.3M | 0.49% |
Sign in (free) to see its 14 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HRFiled August 13, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.